Abstract
Linkage of bacterial capsular polysaccharides to proteins to create conjugate vaccines has had a dramatic impact on the health of children. Although unconjugated polysaccharides are poorly immunogenic in infants and some older children and adults, their covalent coupling with proteins stimulates T cell dependent antigenic recognition that profoundly enhances immunogenicity. In the decade since the introduction and widespread use of Haemophilus influenzae type b polysaccharide conjugate vaccines in the United States, invasive H influenzae infections have become a rarity in childhood. Similarly, the conjugation of polysaccharides of Streptococcus pneumoniae to a derivative of diphtheria toxoid and the addition of pneumococcal conjugate vaccine to infant immunisation schedules carries with it promise for a similar decline in the incidence of invasive pneumococcal disease in paediatric patients.
MeSH Terms
Adult
Antibodies, Bacterial/immunology
Bacterial Capsules/immunology
Child
Clinical Trials as Topic
Dose-Response Relationship, Immunologic
Female
Haemophilus Infections/prevention & control
Haemophilus influenzae type b/immunology
Humans
Immunization/methods
Infant
Licensure
Male
Pneumococcal Vaccines
Serotyping
Streptococcal Infections/prevention & control
Streptococcal Vaccines/immunology,therapeutic use
Streptococcus agalactiae/immunology
Streptococcus pneumoniae/immunology
Tetanus Toxoid/immunology
Vaccines, Conjugate/therapeutic use
Chemicals
Antibodies, Bacterial
Pneumococcal Vaccines
Streptococcal Vaccines
Tetanus Toxoid
Vaccines, Conjugate
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Baker C J
Section of Infectious Diseases, Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA.
Edwards M S
References (22)
22 references, click to expand
-
Group B streptococcal disease in the era of intrapartum antibiotic prophylaxis.
N Engl J Med. 2000 Jan 6;342(1):15-20
PMID: 10620644
-
Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib.
J Infect Dis. 1999 Jan;179(1):142-50
PMID: 9841833
-
Use of capsular polysaccharide-tetanus toxoid conjugate vaccine for type II group B Streptococcus in healthy women.
J Infect Dis. 2000 Oct;182(4):1129-38
PMID: 10979909
-
Invasive group B streptococcal disease in Maryland nursing home residents.
J Infect Dis. 2001 Apr 1;183(7):1138-42
PMID: 11237844
-
Group B streptococcal disease in nonpregnant adults.
Clin Infect Dis. 2001 Aug 15;33(4):556-61
PMID: 11462195
-
Group B streptococcal disease: from trials and tribulations to triumph and trepidation.
Clin Infect Dis. 2001 Sep 15;33(6):751-6
PMID: 11512078
-
Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: a multicenter, seroepidemiology study.
J Infect Dis. 2001 Oct 15;184(8):1022-8
PMID: 11574917
-
Maternal immunization: the influence of liability issues on vaccine development.
Vaccine. 2001 Oct 15;20 Suppl 1:S73-4
PMID: 11587817
-
Effects of alum adjuvant or a booster dose on immunogenicity during clinical trials of group B streptococcal type III conjugate vaccines.
Infect Immun. 2001 Nov;69(11):6696-701
PMID: 11598040
-
Antimicrobial susceptibilities of group B streptococci isolated from patients with invasive disease: 10-year perspective.
Antimicrob Agents Chemother. 2001 Dec;45(12):3623-4
PMID: 11709354
-
The pneumococcus: carriage, disease and conjugate vaccines.
J Med Microbiol. 2002 Feb;51(2):98-104
PMID: 11863272
-
Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection.
N Engl J Med. 1976 Apr 1;294(14):753-6
PMID: 768760
-
Group B streptococcal vaccines.
Rev Infect Dis. 1985 Jul-Aug;7(4):458-67
PMID: 3898306
-
Immunization of pregnant women with a polysaccharide vaccine of group B streptococcus.
N Engl J Med. 1988 Nov 3;319(18):1180-5
PMID: 3050524
-
Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus.
J Clin Invest. 1990 Nov;86(5):1428-33
PMID: 2243123
-
Progress towards the global elimination of neonatal tetanus.
World Health Stat Q. 1992;45(2-3):248-56
PMID: 1462659
-
Immune response to type III group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine.
J Clin Invest. 1996 Nov 15;98(10):2308-14
PMID: 8941648
-
Group B streptococcus bacteremia in nonpregnant adults.
Arch Intern Med. 1997 Jan 27;157(2):213-6
PMID: 9009979
-
Serotype distribution of invasive group B streptococcal isolates in Maryland: implications for vaccine formulation. Maryland Emerging Infections Program.
J Infect Dis. 1998 Apr;177(4):998-1002
PMID: 9534974
-
Antimicrobial susceptibilities of group B streptococci isolated between 1992 and 1996 from patients with bacteremia or meningitis.
Antimicrob Agents Chemother. 1998 Jun;42(6):1517-9
PMID: 9624508
-
Frequent resistance of clinical group B streptococci isolates to clindamycin and erythromycin.
Obstet Gynecol. 1998 Aug;92(2):258-61
PMID: 9699763
-
Invasive disease due to group B Streptococcus in pregnant women and neonates from diverse population groups.
Clin Infect Dis. 2000 Feb;30(2):276-81
PMID: 10671328